Pathway to Cures has announced its investment in SeraGene Therapeutics, a biotech company focused on developing innovative therapies for blood coagulation disorders.

Information on the Target

SeraGene Therapeutics, a Vancouver-based biotechnology firm, specializes in developing innovative therapies for blood coagulation disorders. The company originated from two prestigious blood research institutes: the Versiti Blood Research Institute in Wauwatosa, Wisconsin, and the Center for Blood Research at the University of British Columbia in Vancouver, Canada. Recently, SeraGene has gained recognition in the biotech sector for its advanced RNA-based solutions, supported by the Nanomedicines Innovation Network (NMIN) in Canada. In 2024, SeraGene was awarded the title of 'Company to Watch' at the Life Sciences BC Awards and won the Coup de Coeur prize during Sweet Pharma Day. Their success continued with a nomination as a finalist for the esteemed Eli Lilly Grand Challenge in 2025.

SeraGene's unique technology harnesses RNA modulation to either suppress plasminogen—enhancing clot stabilization—or promote the expression of crucial coagulation-related genes. Delivered through sophisticated lipid nanoparticles (LNPs), their RNA therapies target liver cells directly. This method allows for greater precision in treatment and minimizes the frequency of dosing compared to traditional therapies. The overarching goal of SeraGene is to restore normal blood function and enhance the quality of life for patients, particularly women and those suffering from rare coagulation disorders.

Industry Overview in Canada

The biotechnology industry in Canada is a dynamic and growing sector that continues to attract significant investment and talent. With a robust ecosystem supported by world-class research institutions and innovative companies, Canada is emerging as a leader in biotechnology advance